Short communication: High rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy

AIDS Research and Human Retroviruses

Volumn 29, Issue 6, 2013, Pages 925-930

  Sigaloff, Kim C E ^a,b   Kayiwa, Joshua ^c   Musiime, Victor ^c   Calis, Job C J ^d   Kaudha, Elizabeth ^c   Mukuye, Andrew ^e   Matama, Christine ^e   Nankya, Immaculate ^c   Nakatudde, Lillian ^c   Dekker, John T ^a   Hamers, Raph L ^a,b   Mugyenyi, Peter ^c   Rinke De Wit, Tobias F ^a,b   Kityo, Cissy ^c  

^a PharmAccess Foundation   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d EMMA CHILDREN S HOSPITAL   (Netherlands)

^e Joint Clinical Research Centre   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RILPIVIRINE; TENOFOVIR; THYMIDINE DERIVATIVE; VIRUS RNA;

ALGORITHM; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; CROSS-SECTIONAL STUDY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RNA ANALYSIS; SCORING SYSTEM; UGANDA; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; THYMIDINE; TREATMENT FAILURE; UGANDA; VIRAL LOAD;

EID: 84877866298     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0218     Document Type: Article

References (39)

1. WHO, UNICEF: Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access: Progress report 2011. Available at www.who.int/hiv/ pub/progress-report2011/hiv-full-report-2011.pdf; 2011
2. Gortmaker SL, Hughes M, Cervia J, et al.: Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001;345(21):1522-1528
3. van Rossum AM, Fraaij PL, and de Groot R: Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002;2(2):93-102
4. COHERE: Response to combination antiretroviral therapy: Variation by age. AIDS 2008;22(12):1463-1473
5. Walker AS, Doerholt K, Sharland M, and Gibb DM: Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV paediatric study. AIDS 2004;18(14):1915-1924
6. Abrams EJ, Weedon J, Steketee RW, et al.: Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998;178(1):101-108
7. Menson EN, Walker AS, Sharland M, et al.: Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: Cohort study. BMJ 2006;332(7551): 1183-1187
8. Sigaloff KC, Calis JC, Geelen SP, van Vugt M, and de Wit TF: HIV-1-resistance-Associated mutations after failure of firstline antiretroviral treatment among children in resourcepoor regions: A systematic review. Lancet Infect Dis 2011;11(10):769-779
9. Moorthy A, Gupta A, Bhosale R, et al.: Nevirapine resistance and breast-milk HIV transmission: Effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS One 2009;4(1):e4096
10. Musiime V, Ssali F, Kayiwa J, et al.: Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses 2009;25(10):989-996
11. Sohn AH and Ananworanich J: Highly active antiretroviral therapy for children with treatment failure. HIV Ther 2009;3(5):485-499
12. Boender TS, Sigaloff KC, and Kayiwa J: Barriers to initiation of pediatric HIV treatment in Uganda: A mixed-method study. AIDS Res Treat 2012; PMID 22400106
13. WHO: Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach, 2010 revision. World Health Organization, Geneva, Switzerland, 2010
14. Richard N, Juntilla M, Abraha A, et al.: High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2004;20(4):355-364
15. Johnson VA, Calvez V, Gunthard HF, et al.: 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19(4):156-164
16. Liu TF and Shafer RW: Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006;42(11):1608-1618
17. de Onis M, Onyango A, Borghi E, Siyam A, Nishida C, and Siekmann J: Development of a WHO growth reference for school-Aged children and adolescents. Bull World Health Organ 2007;85:661-668
18. WHO: Anthro for personal computers: Software for assessing growth and development of the world's children. Version 3.2.2, January 2011. In version 3.2.2 ed., Geneva, 2011
19. Ait-Khaled M, Stone C, Amphlett G, et al.: M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS 2002;16(12):1686-1689
20. Ruel TD, Kamya MR, Li P, et al.: Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr 2011;56(1):44-50
21. Charpentier C, Gody JC, Mbitikon O, et al.: Virological response and resistance profiles after 18 to 30 months of first-or second-/third-line antiretroviral treatment: A crosssectional evaluation in HIV type 1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses 2012;28(1):87-94
22. Wamalwa D, Lehman DA, Benki-Nugent S, et al.: Long-Term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy. J Acquir Immune Defic Syndr 2012;online. PMID 23196827
23. Gupta RK, Ford D, Mulenga V, et al.: Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J 2010;29(8): E57-62
24. Zhao Y, Mu W, Harwell J, et al.: Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: An observational cohort study in rural China. J Acquir Immune Defic Syndr 2011;58(1):47-53
25. Saitoh A, Fenton T, Alvero C, Fletcher CV, and Spector SA: Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2007;51(12):4236-4242
26. Riordan A, Judd A, Boyd K, et al.: Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J 2009;28(3):204-209
27. Hazra R, Gafni RI, Maldarelli F, et al.: Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005;116(6):E846-E854
28. Gilead: U.S. Food and Drug Administration Approves New Formulations of Viread- for Use by Children Living With HIV. Gilead press releases, 2012
29. Bartlett JA, Ribaudo HJ, Wallis CL, et al.: Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012;26:1345-1354
30. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al.: A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: The HIV STAR study. Antivir Ther 2012;17(7):1351-1361
31. Bunupuradah T, Kosalaraksa P, Puthanakit T, et al.: Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children. AIDS 2011;25(3):315-323
32. Vingerhoets J, Tambuyzer L, Azijn H, et al.: Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010;24(4):503-514
33. Vigano A, Meroni L, Marchetti G, et al.: Successful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1. Antivir Ther 2008;13(6):839-843
34. Briz V, Palladino C, Navarro M, et al.: Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients. HIV Med 2011;12(7):442-446
35. Penazzato M and Giaquinto C: Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children. Drugs 2011;71(16):2131-2149
36. Orrell C, Harling G, Lawn SD, et al.: Conservation of firstline antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007;12(1):83-88
37. Srasuebkul P, Calmy A, Zhou J, Kumarasamy N, Law M, and Lim PL: Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS Res Ther 2007;4:18
38. Zhou J, Li PC, Kumarasamy N, et al.: Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2009;11(1): 31-39
39. Keiser O, Tweya H, Braitstein P, et al.: Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010;15(2):251-258